Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company whose news flow is driven by developments in its allogeneic CAR-T cell therapy programs and related corporate updates. The company focuses on vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma.
News about Caribou frequently covers clinical trial milestones, including data readouts from the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. Company press releases have highlighted efficacy and durability data in defined patient cohorts, safety profiles that support outpatient administration for vispa-cel, and dose selection and expansion plans for CB-011 in heavily pretreated multiple myeloma populations.
Investors and followers of CRBU can also expect updates on regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug status, as well as communications about planned pivotal trial designs. In addition, Caribou issues quarterly financial results and business updates via press releases and Form 8-K filings, which provide context on its operating runway, research and development spending, and strategic pipeline prioritization.
Another recurring category of news involves conference participation and webcasts, where Caribou’s management and clinical investigators present data at major hematology and oncology meetings and biopharma investor conferences. These events often coincide with new clinical data disclosures or discussions of next steps in trial development.
This news page aggregates such announcements so readers can follow Caribou’s progress in CRISPR-based genome editing, allogeneic CAR-T development, and its lead programs in lymphoma and multiple myeloma. For those tracking CRBU, regular review of this feed helps monitor key clinical, regulatory, and corporate milestones.
Caribou Biosciences, Inc. (Nasdaq: CRBU) has successfully closed its initial public offering of 19,000,000 shares at $16.00 each, raising approximately $304 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 2,850,000 shares. Shares began trading on the Nasdaq on July 23, 2021. BofA Securities, Citigroup, and SVB Leerink acted as joint book-running managers. The registration statements were effective on July 22, 2021, allowing the offering to proceed under SEC regulations.
Caribou Biosciences priced its upsized initial public offering (IPO) of 19,000,000 shares at $16.00 each, aiming for gross proceeds of $304 million. The shares will trade on Nasdaq under the symbol CRBU, beginning July 23, 2021, with the offering expected to close around July 27, 2021. Underwriters have a 30-day option to purchase an additional 2,850,000 shares. BofA Securities, Citigroup, and SVB Leerink are serving as joint book-running managers for the offering.